Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer

NCT05710406 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05710406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05710406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 16, 2023
Completion date
June 1, 2034
Enrollment
1 (actual)
Sites
202

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, microsatellite stable colon carcinoma, stage iib colon cancer ajcc v8, stage iic colon cancer ajcc v8, stage iii colon cancer ajcc v8